Appeal No. 2004-0291
Application No. 09/091,561
Grounds of Rejection
Claims 25-30 and 32-35 stand rejected under 35 U.S.C. 112, first paragraph for
lack of enablement.
We reverse this rejection.
DISCUSSION
Background
The claimed invention is directed to anti-idiotype vascular endothelial growth
factor (VEGF) antibodies. “Two different genes code for the transmembrane tyrosine
kinases identified as VEGF receptors: KDR in man .. or flk-1 in the mouse...”
Specification, page 2. The anti-idiotypic VEGF antibodies recognize the KDR receptor
(or the murine flk-1 receptor) but do not recognize the flt receptor. Specification, page
3. The KDR receptor (or flk-1) is the target of pathological angiogenesis. The
antibodies would not affect quiescent endothelial cells. Id. According to the
specification, VEGF is used to prepare the claimed anti-idiotypic VEGF antibodies which
recognize the KDR receptor (or the murine flk-1 receptor) but do not recognize the flt
receptor. Specification, page 15.
35 U.S.C. § 112, first paragraph
Claims 25-30 and 32-35 stand rejected under 35 U.S.C. 112, first paragraph for
lack of enablement.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007